Biomarker guided therapy in triple-negative breast cancer: Clinical role of ctDNA and PD-L1

Objective Triple-negative breast cancer (TNBC) is a biologically heterogeneous breast cancer subtype characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 (HER2), limiting targeted treatment options and contributing to poor clinical outcomes. This review summarizes the pathological features of TNBC and highlights the theranostic potential of circulating tumour DNA (ctDNA) and programmed death-ligand 1 (PD-L1) as biomarkers for precision oncology. Data Sources Relevant literature on TNBC, ctDNA, and PD-L1 was reviewed, focusing on their molecular characteristics, detection technologies, clinical applications, pivotal clinical trials, and challenges associated with clinical translation. Data Summary ctDNA enables minimally invasive, real-time molecular profiling for detecting tumor-specific genetic alterations, monitoring treatment response, assessing minimal residual disease, and identifying disease recurrence. PD-L1 is a key immune biomarker that predicts responsiveness to immune checkpoint inhibitors. Landmark clinical trials, including KEYNOTE-355, KEYNOTE-522, IMpassion130, IMpassion131, c-TRAK-TN, and BRE12-158, demonstrate that PD-L1-guided immunotherapy improves patient selection and clinical outcomes, whereas ctDNA-guided surveillance facilitates early detection of molecular relapse and risk-adapted therapeutic intervention. Emerging biomarker-driven combination strategies integrating immunotherapy with targeted therapies further support personalized treatment approaches. Despite these advances, challenges related to assay sensitivity, tumor heterogeneity, and biomarker standardization remain. Conclusions ctDNA and PD-L1 have evolved into clinically meaningful theranostic biomarkers that support patient stratification, treatment selection, and disease monitoring in TNBC. Continued validation through prospective clinical trials and standardized biomarker assessment is essential for their routine implementation in precision oncology and for improving patient outcomes.

Authors

Institutions

Publication Details

Journal
Journal of Oncology Pharmacy Practice
Published
2026-11-19
DOI
https://doi.org/10.1177/10781552261507625
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Biomarker guided therapy in triple-negative breast cancer: Clinical role of ctDNA and PD-L1

Sateesha SB, Gokul Chowdappa, Rajamma Abburu Jayaramu, B Bhoomika et al.
Journal of Oncology Pharmacy Practice
Breast Cancer Treatment Studies
article

Biomarker guided therapy in triple-negative breast cancer: Clinical role of ctDNA and PD-L1

Sateesha SB, Gokul Chowdappa, Rajamma Abburu Jayaramu, B Bhoomika, S Rajesh, B Jeeva Jothi, B.G. Divyasree
article en

Abstract

Objective Triple-negative breast cancer (TNBC) is a biologically heterogeneous breast cancer subtype characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 (HER2), limiting targeted treatment options and contributing to poor clinical outcomes. This review summarizes the pathological features of TNBC and highlights the theranostic potential of circulating tumour DNA (ctDNA) and programmed death-ligand 1 (PD-L1) as biomarkers for precision oncology. Data Sources Relevant literature on TNBC, ctDNA, and PD-L1 was reviewed, focusing on their molecular characteristics, detection technologies, clinical applications, pivotal clinical trials, and challenges associated with clinical translation. Data Summary ctDNA enables minimally invasive, real-time molecular profiling for detecting tumor-specific genetic alterations, monitoring treatment response, assessing minimal residual disease, and identifying disease recurrence. PD-L1 is a key immune biomarker that predicts responsiveness to immune checkpoint inhibitors. Landmark clinical trials, including KEYNOTE-355, KEYNOTE-522, IMpassion130, IMpassion131, c-TRAK-TN, and BRE12-158, demonstrate that PD-L1-guided immunotherapy improves patient selection and clinical outcomes, whereas ctDNA-guided surveillance facilitates early detection of molecular relapse and risk-adapted therapeutic intervention. Emerging biomarker-driven combination strategies integrating immunotherapy with targeted therapies further support personalized treatment approaches. Despite these advances, challenges related to assay sensitivity, tumor heterogeneity, and biomarker standardization remain. Conclusions ctDNA and PD-L1 have evolved into clinically meaningful theranostic biomarkers that support patient stratification, treatment selection, and disease monitoring in TNBC. Continued validation through prospective clinical trials and standardized biomarker assessment is essential for their routine implementation in precision oncology and for improving patient outcomes.

Journal of Oncology Pharmacy Practice
KLE Academy of Higher Education and Research (IN)
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon